<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02802423</url>
  </required_header>
  <id_info>
    <org_study_id>BLI-1401-2-01</org_study_id>
    <nct_id>NCT02802423</nct_id>
  </id_info>
  <brief_title>Phase I/II, Evaluate the Safety and Efficacy of BLEX 404 With Docetaxel in Patients With Advanced/Metastatic Triple Negative Breast Cancer.</brief_title>
  <official_title>A Multi-Center, Randomized, Double Blind, Placebo-Controlled, Phase IIA Study to Evaluate the Safety and Efficacy of BLEX 404 Oral Liquid With Adjuvant Chemotherapy in Patients With Triple Negative Breast Cancer (TNBC) After Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioLite, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioLite, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to determine the safety and recommended dose level (RDL)&#xD;
      of BLEX 404 Oral Liquid combined with Docetaxel monotherapy in a 21-day schedule. The&#xD;
      secondary purpose is to assess the efficacy and safety of BLEX 404 Oral Liquid combined with&#xD;
      Docetaxel monotherapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2022</start_date>
  <completion_date type="Anticipated">February 28, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase I: Dose-limiting toxicity (DLT) observation</measure>
    <time_frame>3 weeks (1 cycle)</time_frame>
    <description>Presence or absence of dose-limiting toxicity (DLT) related to BLEX 404 Oral Liquid for each patient during first cycle of Docetaxel monotherapy to determine the recommended dose level (RDL).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase II: Overall response rate (PR + CR)</measure>
    <time_frame>12 weeks (4 cycles)</time_frame>
    <description>Overall response rate (PR + CR) after 4 cycles of combination use in BLEX 404 + Docetaxel monotherapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase II: Overall response rate (PR + CR)(at least 1 cycle)</measure>
    <time_frame>at least 3 weeks (1 cycle)</time_frame>
    <description>Overall response rate (PR + CR) after at least 1 cycle of combination use in BLEX 404 + Docetaxel monotherapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Incidence of grade 3/4 hematological toxicity</measure>
    <time_frame>3 weeks (1 cycle)</time_frame>
    <description>Rate of grade 3/4 hematological toxicity of each cycle.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>3 weeks (1 cycle)</time_frame>
    <description>Examination of quality of life by EORTC QLQ-C30 questionnaire of each cycle.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Triple Negative Breast Cancer</condition>
  <arm_group>
    <arm_group_label>BLEX 404 Oral Liquid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During Phase I study (dose escalation), a standard 3+3 design will be followed, and the dose range is 3 to 10 mg/kg BID. The recommended dose level (RDL) for the Phase II study is defined as the dose level with 0 to 1 DLT observed during cycle I of Docetaxel monotherapy among 6 patients in the Phase I study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BLEX 404 Oral Liquid</intervention_name>
    <description>BLEX 404 Oral Liquid is administered twice daily during the Docetaxel monotherapy period. The dose of Docetaxel is 75 mg/m2 IV, 21 days a cycle.</description>
    <arm_group_label>BLEX 404 Oral Liquid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Females aged 20 - 70 years old at the time of signing the ICF.&#xD;
&#xD;
          2. Patients with histologically or pathologically diagnosed with advanced/metastatic&#xD;
             triple negative (ER-, PR-, and HER2-negative) breast cancer.&#xD;
&#xD;
               1. ER =&lt; 10% by immunohistochemistry (IHC) tumor staining;&#xD;
&#xD;
               2. PR =&lt; 10% by IHC tumor staining;&#xD;
&#xD;
               3. HER2-negative defined as one of the following: 0 or 1+ by IHC, or 2+ by IHC and&#xD;
                  fluorescence in situ hybridization (FISH)-negative (ratio &lt; 2.0).&#xD;
&#xD;
          3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.&#xD;
&#xD;
          4. Adequate hematologic function defined as: absolute neutrophil count (ANC) greater than&#xD;
             or equal to 2,000/μL; platelets count greater than or equal to 100,000/μL; hemoglobin&#xD;
             must be greater than or equal to 10 g/dL (can be corrected by growth factor or&#xD;
             transfusion).&#xD;
&#xD;
          5. Adequate hepatic function defined as: serum bilirubin less than or equal to 1.5-fold&#xD;
             upper limit of normal (ULN); aspartate aminotransferase (AST), alanine&#xD;
             aminotransferase (ALT), and alkaline phosphatase (ALP) less than or equal to 3-fold&#xD;
             ULN.&#xD;
&#xD;
          6. Adequate renal function with: serum creatinine less than or equal to 1.3 mg/dL or&#xD;
             calculated creatinine clearance greater than or equal to 60 mL/minute according to the&#xD;
             Cockcroft and Gault formula.&#xD;
&#xD;
          7. Women must be either of non-child bearing potential, or women with child-bearing&#xD;
             potential agree to use effective a highly contraceptive method or a contraceptive&#xD;
             implant, exception of hormonal contraception (estrogen/progesterone), from time of&#xD;
             Screening Visit until 30 days after study drug discontinuation.&#xD;
&#xD;
          8. Planning to receive Docetaxel monotherapy.&#xD;
&#xD;
          9. Willing and able to comply with all aspects of the treatment protocol.&#xD;
&#xD;
         10. Provide written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient with brain metastasis.&#xD;
&#xD;
          2. Patient with autoimmune disease that requires systemic steroids or immunosuppression&#xD;
             agents.&#xD;
&#xD;
          3. Current enrollment in another clinical study or used any investigational drug or&#xD;
             device within the past 28 days preceding informed consent.&#xD;
&#xD;
          4. Patients with following treatment prior to Docetaxel monotherapy: chemotherapy,&#xD;
             immunotherapy, or biologic systemic anticancer therapy within 21 days of study entry&#xD;
             (42 days for mitomycin and nitrosoureas); prior taxanes; radiation therapy within 28&#xD;
             days (3 months for bone marrow exposure 20%); hormonal therapy within 4 weeks.&#xD;
&#xD;
          5. Known history of human immunodeficiency virus (HIV) infection.&#xD;
&#xD;
          6. Existing anticancer treatment-related toxicities of Grades greater than or equal to 2&#xD;
             (except for alopecia and neuropathy) according to Common Terminology Criteria for&#xD;
             Adverse Events (CTCAE v4.03).&#xD;
&#xD;
          7. Patients with Grade &gt; 2 neuropathy.&#xD;
&#xD;
          8. Patient has an active infection requiring systemic therapy.&#xD;
&#xD;
          9. History of concomitant medical conditions or infectious diseases that, in the opinion&#xD;
             of the investigator, would compromise the subject's ability to safely complete the&#xD;
             study.&#xD;
&#xD;
         10. Clinically significant electrocardiogram (ECG) abnormality, including a marked&#xD;
             baseline prolonged QT/QTc ([QT interval/corrected QT interval].&#xD;
&#xD;
         11. Ascertained hypersensitivity to any component of investigational product used in the&#xD;
             study.&#xD;
&#xD;
         12. Uncontrolled nausea or vomiting or any symptom that would prevent the ability to&#xD;
             comply with daily BLEX 404 Oral Liquid treatment.&#xD;
&#xD;
         13. Judged to be not applicable to this study by investigator such as difficulty of&#xD;
             follow-up observation, psychiatric disorder, with any other serious diseases/medical&#xD;
             history.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard King, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>American BriVision Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hsien-Ming Wu, Master</last_name>
    <phone>886-3-657-9631</phone>
    <phone_ext>13</phone_ext>
    <email>sonnywu@bioliteinc.com</email>
  </overall_contact>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>June 13, 2016</study_first_submitted>
  <study_first_submitted_qc>June 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2016</study_first_posted>
  <last_update_submitted>July 20, 2021</last_update_submitted>
  <last_update_submitted_qc>July 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TNBC</keyword>
  <keyword>Breast cancer</keyword>
  <keyword>Triple negative</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

